In clinical trials, the drug was shown to almost double the median survival time for patients with pancreatic cancer.

Join PanCAN on Thursday, June 25, at 11 a.m. PT / 2 p.m. ET, for a webinar focused on KRAS and pancreatic cancer. Our panel ...

Researchers at McGill University have discovered a centuries-old genetic mutation that helps to explain why some ...

Last month, Revolution Medicines’ RAS inhibitor doubled survival in a Phase 3 pancreatic cancer trial. On the biotech’s heels are Immuneering, Actuate Therapeutics, Erasca and more, looking to improve ...

The new oral medication, daraxonrasib, has been shown to meaningfully extend the lives of patients with late-stage pancreatic ...

By Deena Beasley and Nancy Lapid May 14 (Reuters) - U.S. cancer centers are scrambling to enroll patients in an early access ...

Researchers have uncovered an unexpected weakness in pancreatic cancer involving damaged mitochondria and a powerful ...

More than 50,000 individuals in the U.S. succumb to pancreatic cancer each year, with the majority being diagnosed at stage ...

Scientists long ago identified their target: a smooth-surfaced protein inside cells, called KRAS, that is altered in certain ...

A new stem-cell-derived model suggests human pancreatic cells require multiple genetic failures before becoming cancerous and ...